Free Republic

A recent study by 11 scientists with the Mayo Clinic suggests that boys who take puberty-blocking drugs could be at risk of developing atrophied testicles and long-term infertility issues, despite claims that such drugs are reversible.The study, published in March and titled "Puberty Blocker and Aging Impact on Testicular Cell States and Function," analyzed testicular tissue samples from 87 patients under age 18.Sixteen of the boys identified as girls, and nine of them took puberty blockers. Two of the nine on puberty blockers "exhibited abnormalities" in their testicles, states the study hosted on the website of Cold Spring Harbor Laboratory...

‘Gender-affirming care’ is starting to run up against reality and it is getting really ugly for the people who pushed sterilization and mutilation on children. Recently, after journalist Michael Shellenberger released ‘the WPATH files,’ the credibility of individuals and organizations who have embraced trans activism has been called into question, and for one very good reason: they have no credibility. Now, nations such as the UK and France are either banning these practices outright or considering bans as more evidence comes out that justifies the French Senate calling ‘gender-affirming care’ one of the greatest medical scandals in history. The latest...

England’s National Health Service banned the use of puberty blockers for children seeking treatment for gender dysphoria, citing limited research. Puberty blockers, or gonadotropin-releasing hormone analogues (GnRHa), is a class of drugs that suppresses sex hormones in adolescents by continually stimulating the pituitary gland. It will now only be available to children in limited ways, such as clinical trials. The NHS’s website said, “Puberty blockers (gonadotrophin-releasing hormone analogues) are not available to children and young people for gender incongruence or gender dysphoria because there is not enough evidence of safety and clinical effectiveness.” NHS England had previously ordered the London-based...

Centred on the University of Lille, France, in September 2022, a group of international researchers reported in the prestigious journal Science that the progressive devolution in mental abilities of people suffering from Down Syndrome (DS) could be attributed to an associated reduction in the production of a particular hormone. They based their assertion on the results of experiments they had performed on genetically engineered mouse models of DS and on a small group of adult human sufferers of DS, in all of which the levels of the hormone had been restored to normal by various experimental means.[1] The researchers report...

Drug maker Abbvie recently won a court case in which they sued Takeda Pharmaceutical, the company responsible for the production of their drug Lupron. In the case, Abbvie alleges that Takeda created a shortage of the drug by intermittently shutting down one of its plants. A judge found that Takeda Takeda was in breach of its contract with Abbvie and has ordered the to pay most of the $480.6 million it sought. Lupron may sound familiar to you because it has been at the center of the debate art whether or not children should be allowed to suppress puberty to...

Britain’s National Health Service recently made a landmark decision that the United States should copy. True, the country’s system of socialized medicine continues to ration treatments deemed too expensive by government bureaucrats. Importing the NHS to the United States would exacerbate the problems in our health care system. But at least the NHS is listening when it comes to protecting young children from dangerous and experimental treatments. That’s the takeaway from the recent news that the health system has officially recommended limiting access to puberty-suppressing drugs: “outside of a research setting, puberty-suppressing hormones should not be routinely commissioned for children...

Britain’s National Health Service will no longer routinely prescribe puberty blockers to children amid concerns over a lack of evidence on the impact of the so-called gender-affirming drugs. In what is being described as a historical moment, the UK’s state healthcare provider will no longer be prescribing children with life-altering puberty blockers except in exceptional cases or in the context of clinical research. According to a report from the BBC, the decision followed a report which admitted that there were “gaps” in evidence surrounding the use of the controversial drugs on children believed to be experiencing gender dysphoria. The change...

The Truth About ‘Puberty Blockers’ The FDA hasn’t approved them for gender dysphoria, and their effects are serious and permanent.